ArticleFrontiers in medicine2025
Prognostic impact of angiotensin-converting enzyme inhibitors and dexmedetomidine in acute respiratory distress syndrome: a MIMIC-IV-based retrospective cohort analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute respiratory distress syndrome (ARDS) is a prevalent condition in the respiratory department and intensive care unit that considerably influences prognosis. Prior research has demonstrated that angiotensin-converting enzyme inhibitors (ACEIs) or dexmedetomidine can improve the prognosis of ARDS. Nonetheless, the combinatorial effect of ACEIs and dexmedetomidine on the prognosis of ARDS remains to be investigated. Method: A retrospective study was conducted using data from 696 patients with ARDS collected from the Medical Information Mart for Intensive Care IV database. Subsequently, a Cox regression model was constructed to screen for meaningful variables. Moreover, a multi-model Cox regression was constructed to exclude the interference of confounding factors and explore the effects of ACEIs alone, dexmedetomidine alone, and ACEIs combined with dexmedetomidine on the prognosis of patients with ARDS. Finally, it was verified by plotting the Kaplan-Meier survival curve. Result: The survival rates of patients with ARDS within days 28, 60, 90, 180, and 365 after admission were 61.6, 57.0, 55.9, 53.7, and 51.3%, respectively. The results of the multi-model Cox regression revealed that compared with the application of ACEIs or dexmedetomidine alone, ACEIs combined with dexmedetomidine have a synergistic effect on reducing the risk of death in patients with ARDS. The conclusion of the Kaplan-Meier survival curve is consistent with that of the Cox regression. Conclusion: In terms of reducing the risk of death in patients with ARDS, the combined application of dexmedetomidine and ACEIs may have a better effect than monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.